JP2007531717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531717A5 JP2007531717A5 JP2007504513A JP2007504513A JP2007531717A5 JP 2007531717 A5 JP2007531717 A5 JP 2007531717A5 JP 2007504513 A JP2007504513 A JP 2007504513A JP 2007504513 A JP2007504513 A JP 2007504513A JP 2007531717 A5 JP2007531717 A5 JP 2007531717A5
- Authority
- JP
- Japan
- Prior art keywords
- integer
- general formula
- following general
- compound
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 229920001451 polypropylene glycol Polymers 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000693 micelle Substances 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000017488 activation-induced cell death of T cell Effects 0.000 claims 1
- 210000001557 animal structure Anatomy 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000030248 negative regulation of fibroblast proliferation Effects 0.000 claims 1
- 229960003742 phenol Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55708704P | 2004-03-26 | 2004-03-26 | |
| US60/557,087 | 2004-03-26 | ||
| PCT/IB2005/001160 WO2005092305A2 (en) | 2004-03-26 | 2005-03-24 | Compounds for treating aids and other diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007531717A JP2007531717A (ja) | 2007-11-08 |
| JP2007531717A5 true JP2007531717A5 (https=) | 2008-05-08 |
| JP4939396B2 JP4939396B2 (ja) | 2012-05-23 |
Family
ID=34969419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504513A Expired - Fee Related JP4939396B2 (ja) | 2004-03-26 | 2005-03-24 | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7674829B2 (https=) |
| EP (1) | EP1750691B1 (https=) |
| JP (1) | JP4939396B2 (https=) |
| AU (1) | AU2005225239B2 (https=) |
| CA (1) | CA2560922C (https=) |
| IL (1) | IL178094A (https=) |
| WO (1) | WO2005092305A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642290B2 (en) | 2002-10-03 | 2010-01-05 | Novaremed Limited | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| DE102004025220A1 (de) * | 2004-05-22 | 2005-12-08 | Bayer Cropscience Gmbh | Ölsuspensionskonzentrat |
| JP4939396B2 (ja) | 2004-03-26 | 2012-05-23 | ノヴァレメッド リミテッド | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
| JP2009531283A (ja) | 2006-02-02 | 2009-09-03 | アラーガン、インコーポレイテッド | 眼系疾患の処置のための組成物および方法 |
| JP5225264B2 (ja) * | 2006-05-09 | 2013-07-03 | ノベアメド・リミテッド | 細胞増殖障害の処置 |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| US8802734B2 (en) * | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| CN102821761B (zh) * | 2009-09-09 | 2015-06-10 | 诺瓦麦有限公司 | 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺 |
| GB201116335D0 (en) * | 2011-09-21 | 2011-11-02 | Novaremed Ltd | A method of treating or preventing affective disorders |
| AU2012348529B2 (en) * | 2011-12-08 | 2017-03-30 | Novaremed Ltd. | Isolated stereoisomeric forms of (S) 2-N (3-O-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide |
| US11891350B2 (en) | 2019-01-23 | 2024-02-06 | Novaremed Ltd. | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity |
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
| WO2026037478A1 (en) | 2023-08-11 | 2026-02-19 | Novaremed AG | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2908691A (en) * | 1958-07-14 | 1959-10-13 | Searle & Co | Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto |
| ZA732136B (en) * | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4908322A (en) * | 1985-09-06 | 1990-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Derivatization of amines for electrochemical detection |
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO1994003427A1 (en) * | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| JP2848232B2 (ja) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
| AU1463997A (en) | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
| WO1997029079A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| AU2002224139A1 (en) | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Ppar (peroxisome proliferator activated receptor) activators |
| US7642290B2 (en) * | 2002-10-03 | 2010-01-05 | Novaremed Limited | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| JP4939396B2 (ja) * | 2004-03-26 | 2012-05-23 | ノヴァレメッド リミテッド | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
| RU2309144C2 (ru) | 2005-03-25 | 2007-10-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств |
| JP5225264B2 (ja) * | 2006-05-09 | 2013-07-03 | ノベアメド・リミテッド | 細胞増殖障害の処置 |
| KR20100087099A (ko) | 2007-09-17 | 2010-08-03 | 아카데미아 시니카 | 플렉트란투스 암보이니쿠스 추출물에 의해 염증 및 염증-관련 질병을 치료하기 위한 조성물 및 방법 |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| CN101503370B (zh) | 2009-03-02 | 2012-08-22 | 上海应用技术学院 | 一种n-环丙基-反-2-顺-6-壬二烯酸酰胺的合成方法 |
| CN101503373B (zh) | 2009-03-13 | 2013-07-24 | 山东大学 | 2-氨基-1-(4-硝基苯基)-1-乙醇类金属蛋白酶抑制剂及其制备方法和用途 |
-
2005
- 2005-03-24 JP JP2007504513A patent/JP4939396B2/ja not_active Expired - Fee Related
- 2005-03-24 EP EP05731294.4A patent/EP1750691B1/en not_active Expired - Lifetime
- 2005-03-24 US US11/089,157 patent/US7674829B2/en not_active Expired - Fee Related
- 2005-03-24 AU AU2005225239A patent/AU2005225239B2/en not_active Ceased
- 2005-03-24 CA CA2560922A patent/CA2560922C/en not_active Expired - Fee Related
- 2005-03-24 WO PCT/IB2005/001160 patent/WO2005092305A2/en not_active Ceased
-
2006
- 2006-02-23 US US11/362,567 patent/US7754771B2/en not_active Expired - Fee Related
- 2006-09-14 IL IL178094A patent/IL178094A/en active IP Right Grant
-
2010
- 2010-07-12 US US12/834,432 patent/US8252843B2/en not_active Expired - Fee Related